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Abstract 
Objective: To evaluate the utility of an online self-report registry for patient self monitoring and 
management (PSM) of warfarin therapy.  
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Methods: A prospective observational study of UK based patients undertaking PSM and recording 
their INR data via an online registry. Consenting participants recorded INR test dates, results and 
warfarin dosages using the online registry for a period of 12 months. Participants reported 
demographic data, disease characteristics and treatment-related adverse events and provided feedback 
via a survey. Data accuracy was assessed through comparison of INR results recorded online with 
results stored on 19 INR testing devices. Percentage time spent within therapeutic range (TTR) was 
also examined. 
 
Results:  Eight seven percent (39/45) completed the study period. Age ranged from 26-83 years, 44% 
had undertaken PSM for >5 years. Sixty six percent (25/38) reported that the registry was easy to 
navigate and use. Forty two participants contributed a total of 1669 INR results. Agreement between 
self-reported INR results and source INR data was high (99%). Mean therapeutic time in range (TTR) 
was 76% (SD 18.58) with 83% having >60% TTR.   
 
Conclusion: Findings suggest that an online PSM registry is feasible, accurate and acceptable to 
patients. These findings require confirmation in a larger cohort of PSM patients. An online self report 
registry could provide a valuable resource for gathering real world evidence of clinical effectiveness 
and safety of these developing models of care.  
 
 
Key words: Oral anticoagulation, Warfarin, Self-monitoring, Patient registry, self-reporting. 
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Introduction 
Patient self monitoring and self management of oral anticoagulation therapy with vitamin K 
antagonists (mainly warfarin in the UK) involve the patient being responsible for testing their 
International Normalised Ratio (INR) using a finger prick, blood sample and a point of care (POC) 
coagulometer device 1. Patients self managing their warfarin therapy interpret their INR test result 
themselves and adjust their warfarin dose and test frequency accordingly. In the patient self 
monitoring model, the patient contacts a health professional for advice on warfarin dose and INR test 
frequency.   
The clinical effectiveness of patient self monitoring and self management of oral anticoagulation has 
been demonstrated in a number of controlled trials 2-4. A systematic review and meta-analysis 
demonstrated that self monitoring and self management are associated with a significant one-third 
reduction in major haemorrhage and self management with a significant reduction in death 5. Current 
NICE guidelines related to the use two point of care coagulometers for self-monitoring of 
anticoagulation state that self-monitoring and self-management are likely to be clinically effective and 
that self management is highly cost effective whereas self monitoring is not 6.  
Whilst there is a large body of trial evidence supporting patient self monitoring and management of 
warfarin therapy, little is known, about the effectiveness and safety of these models of care outside 
trial conditions apart from small follow up studies 7;8. The findings of the follow up  studies are 
limited as patient populations are highly selected and as such unrepresentative of the wider population 
undertaking self monitoring or management. A recent Cochrane review of self-monitoring and 
management compared to standard management acknowledged a lack of generalisablity of trial 
findings and suggested that large population-based observational studies are required to confirm the 
safety and effectiveness of these models of care in routine clinical practice 9. 
In the UK, it is estimated that around 1-2% of the 1.2 million patients receiving warfarin therapy are 
undertaking self monitoring or self management of warfarin therapy 10. Of concern is the difficulty 
with systematically collecting data related to the utility of this model of care to reflect typical self 
management practices and patient characteristics, as patients undertaking self management keep their 
own records and do not necessarily fully engage with oral anticoagulation services.  
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One approach to overcoming this problem would be through a registry which offers the opportunity to 
gather data to better reflect real world practices and outcomes. Registries have previously been 
utilised for population based epidemiological research as they typically involve larger, more diverse 
populations than trials 11;12.  
Online registries have been successfully developed to track patient satisfaction with chronic 
medication and to report upon real-world side effects of medications 13. Also self-reported data from 
internet based patient communities have been developed for planning and developing effective 
research proposals 14;15.  Substantial patient benefits have been shown in other studies utilising the 
internet to deliver education and  interventions for self care of chronic disease and for electronic 
symptom reporting clearly demonstrating the potential of the internet to improve patient outcomes 16-
18. Internet based, direct-to-patient systems which utilise a combination of decision support software 
and expert  supervision have been shown to facilitate patient self monitoring of warfarin therapy and 
improve INR control.19-22  
Therefore an online patient self-report registry would offer a practical way to capture data related to 
self- monitoring/management and further extend the clinical effectiveness and safety evidence base 
for these models of care. The usefulness of such a registry depends upon the quality of the data 
recorded. It is unclear, whether patients would be willing and able to contribute data using an online 
registry.  
The aim of the current study was therefore to evaluate the utility of an online self-report register for 
patients self managing their oral anticoagulation and explore patient outcome data.  
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Methods  
Study design  
A prospective observational study of patients undertaking self- management of oral anticoagulation 
therapy and recording their INR data via an online registry was conducted between December 2010–
December 2011. Ethical review and approval for the study was provided by the institutions ethical 
review board.   
 
Recruitment and eligibility  
Participants were recruited via advertisement i) in an electronic newsletter, ii) a quarterly magazine, 
iii) on two websites and iv) at a conference. Individuals managing their warfarin therapy, aged >18 
years with internet access were eligible to participate. The study information sheet was available via 
the online registry or from the research team. Those wishing to participate completed a consent form 
and registered their name and contact details using the online registry.  
 
Collection of data  
Consenting participants were asked to record INR test dates, results and warfarin dosages using the 
online registry for a 12 month period. Participants also recorded demographic data, disease 
characteristics; methods used for quality control and dosing and treatment related bleeding or 
thrombotic events. To reduce missing data, weekly data checks were undertaken to identify missing 
INR results and generate reminder emails. Participants providing their email contact details were 
invited to complete a survey to ascertain their opinions and experience of using the online registry and 
suggestions of how the registry could be improved. Participants continued to receive dosing advice 
and clinical supervision as previously arranged with their direct care team. The online register was 
used for reporting of data only. No advice on dosage adjustment and frequency of testing was 
provided via the online registry. The research team and the participants had access to the registry data. 
The participants’ clinical supervisors and direct care team were not provided with access to the 
registry.  
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Structure and content of the online registry  
The design and development of the online self-report registry was informed by patients, health 
professionals and review of websites designed for by older people. 23 The registry home page 
contained links to study information and demonstrations of how to provide consent and data. The data 
collection forms each comprised i) a header; describing the type of data to be recorded ii) a bookmark; 
detailing the current question to be answered and iii) a map; detailing how many more questions were 
to be answered. Guides to aid interpretation of questions were provided. 
 
Data analysis 
The quality of the self-reported data was evaluated through comparison of the INR test results and 
dates recorded online with the results and dates downloaded directly from the POC devices of 19 
randomly selected participants. These data were also used to determine therapeutic INR control 
defined by percentage time spent within therapeutic range for each participant (TTR).  TTR was 
calculated using the Rosendaal equation which assumes a liner change between INR test results 24. 
The paired t test was used to compare TTR derived from the INR data stored on the POC device with 
TTR calculated from the INR data recorded online.  
Patient reported treatment related bleeding or thrombotic events were categorized as serious and non 
serious adverse event. Serious adverse bleeding events were defined as clinically overt bleeding 
associated with hospitalization; a blood transfusion; or a fatal outcome. Non serious adverse bleeding 
events were defines as overt bleeding associated with medical intervention, unscheduled contact (visit 
or telephone call) with a physician, or associated with discomfort for the subject such as pain or 
impairment of activities of daily life. A diagnosis of deep vein thrombosis, pulmonary embolism or 
stroke constituted serious thrombotic events.  
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Results 
The online consent form was completed by 45 patients. Thirteen percent (6/45) did not contribute all 
study data points or complete the 12 month study period (figure 1). One participant used the register 
to record data related to age and gender only. Two participants used the register to record 
demographic data, indication for and duration of warfarin therapy and model of care utilised however, 
did not record INR data. Three participants discontinued using the online register after recording; 
demographic data, indication for and duration of warfarin therapy, model of care utilised and INR 
data for a period of 3 months. A total of 39/45 (87%) completed the 12 month study period and 
provided all study data points.  
 
Sixty nine percent (31/45) were male (table 1). Age ranged from 26 to 83 years with 29/45 (64%) 60 
years or more. The main indications for warfarin were; mechanical heart valve 21/44 (48%), atrial 
fibrillation 11/44 (25%) and pulmonary embolism 5/44 (11%). The length of time participants had 
been taking warfarin ranged from less than 12 months 1/44 (2%) to more than 5 years 24/44 (55%). In 
terms of model of care utilised, 25/44 (57%) of the cohort were self managing their warfarin therapy 
and 19/44 (43%) were self monitoring their INR. 
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Therapeutic time in range and adverse events 
Forty two of the forty five (93%) participants recorded 1669 INR results and contributed 36.9 patient 
years of data. The mean frequency of INR testing was 16 days (range 3-92 days).  The mean TTR of 
the cohort was 76% (SD 18.58), TTR ranged from 22-100% with 83% spending more than 60% time 
in range (the standard recommended by the British Society for Haematology)25. A total of 58 adverse 
events were reported by 17/ 42 (40%) participants. Four were categorised as serious adverse events 
(11.5 per 100 patient years) and included one post-operative bleed, one suspected pulmonary 
embolism, one suspected deep vein thrombosis and one transient ischemic attack.  
 
Quality control results 
The methods of external quality assurance (EQA) used by the cohort varied, 17/44 (38.6%) compared 
INR results obtained on two POC devices (their own device and a clinic owned device) using 
simultaneous capillary blood samples. Ten (22.7%) compared the INR result obtained using a 
capillary blood sample and their POC device with the INR result obtained by the hospital laboratory 
using a venous blood sample. Eight (18.2%) reported that they had used both methods of EQA and 
9/44 (20.5%) stated that they had not used any method of EQA.     
 
Administration of the online registry  
Two hundred and fifty one telephone helpline queries were logged. Sixteen percent of calls were 
received during the initial three months from 17/42 (40%) participants requiring help using the online 
registry to record their data. Overall, 25/42 (60%) did not use the helpline.  
 
Data quality 
A total of 926 INR test results and dates were downloaded from 19 POC devices. Of these 118/926, 
(13%) were not recorded online. (Figure 2) The paired t test showed no significant differences in 
individual participants online TTR compared with the TTR derived from INR results stored on the 
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POC device  (p=0.999).   805/808 (99.6%) of the INR results reported online were accurately 
recorded. 
 
Participant evaluation 
Participant surveys were returned by 38/44 (86%), of which 37/44 (84%) were fully completed. 
Eighty nine percent (33/37) reported that they had not experienced any problems accessing the 
register and 66% (25/38) found the online system easy to navigate and use. Seventy one percent 
(27/38) stated they would be happy to carry on recording data. Fifty five percent reported that they 
would like to be able to review their past INR results, 50% to review their previous warfarin doses, 
24% would have liked dosing advise and 18% would have liked to access education materials.  
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Discussion  
This paper reports the utility of an online self-report register for patients self managing their oral 
anticoagulation and explores patient outcome data. The high study completion rate, accuracy of 
reporting and positive participant feedback observed in this study suggest that internet based data 
acquisition techniques can be used to enable sharing of patient outcomes data and confirm the 
feasibility of a longitudinal online PSM registry.  
Participants recorded their INR data, warfarin dosage and treatment associated adverse events via an 
online self-report registry for a period of 12 months. To our knowledge this is the first study to 
examine the feasibility of an online self- report PSM registry to gather real world data related to the 
clinical effectiveness and safety of this developing model of care.  
In general, participants required very little support when recording their data online and few queries 
were received via the helpline. In addition, participant feedback indicated that the majority were 
willing to continue recording their data online.  
The online registry allowed recruitment and collection of data from a cohort of patients undertaking 
PSM across the UK with 87% of those recruited completing the 12 month study period. The cohort 
comprised a diverse group of patients in terms of age, indication for and duration of warfarin therapy 
and experience of PSM. More men than women were recruited however; the proportion of male to 
female participants was similar to that observed in trials of PSM 2;7. All age groups were represented 
in the current study, although the majority of the population were aged 60 years or more, which 
reflects PSM trial findings. A reason for this may be that older people typically use the internet for 
health related activities and anecdotal evidence suggests older people are more likely to self monitor 
or manage their anticoagulation 9. It has been suggested that internet based medical registries are 
subject to selection bias based upon internet accessibility and use 26;27.  Recently published data, 
however, demonstrate that 83% of households now have access to the internet and 72% of adults in 
the UK have shopped online 28.   
In contrast to trials of PSM, the study population comprised a greater proportion of patients with a 
mechanical heart valve than with atrial fibrillation 2;3;7. Further research in the real world setting is 
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required to confirm the characteristics of this patient group. It would be interesting to also include 
children in further work as they are a group who benefit from PSM in terms of missed school days 
and are likely to be highly motivated to use an online system. 
It was encouraging to see that the data entered was 99% accurate when comparing INR results 
recorded online with source data obtained from the POC device. Some incomplete data reporting was 
observed, however, this did not have a statistically significant impact upon overall percentage time 
spent within therapeutic range (TTR) during the study period. The reminder emails were effective in 
improving INR data capture. The reasons for incomplete INR data recording were not collected 
therefore it is difficult to suggest additional strategies to improve reporting of INR data.  
Therapeutic INR control varied in the patient cohort. However, in accordance with studies of PSM 
outside of trial conditions, 7;8 around 80% of the current PSM cohort was within therapeutic range 
more than 60% of the time. These findings indicate that PSM can be effective in the real world 
setting. Due to the small sample size, calculation and comparison of therapeutic control between the 
groups self managing and self testing was not undertaken.  
One concern related to PSM is that INR tests would be undertaken too frequently which my reduce 
both clinical and cost effectiveness. This study showed an average testing frequency of 16 days, 
equating to around 23 tests per year which is similar to the number of tests per year for self 
monitoring  reported in the NICE guideline document currently out for consultation 29.  
The overall incidence of serious adverse events, mainly thrombotic episodes, was higher than that 
reported in trials of PSM patients receiving long term anticoagulation for any indication 2 and after 
mechanical heart valve insertion 30. The reasons for this are unclear and need further investigation. A 
limitation of this study was that verification of self-reported treatment related adverse events with the 
clinical records was not possible. If an online self-report registry is to be a useful resource, research to 
evaluate the validity of self -reported warfarin related adverse events and/or strategies to verify patient 
recorded treatment associated adverse events are required. Further limitations of the current study are 
the small sample size and relatively short duration of follow-up.  
In the current study dosing advice was not provided to participants via the online registry. For those 
undertaking self testing, specific details of the arrangements for adjustment of dosage were not 
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captured. Several studies have however shown improvements in therapeutic control in patients that 
self-test and have direct access to an internet based decision support system or clinical supervisor for 
dosing advice.19;21;22 In a prospective, single-group, before and after study, O’ Shea et al demonstrated 
an increase in therapeutic time in range from 63% in the anticoagulation clinic to 74% during internet- 
supervision. 21  Similarly, a subsequent randomized, cross over study, using the same internet based 
system, reported an improvement in therapeutic control from 59% to 74%. 19 More recently, 
significant improvements in TTR (66% to 78%) have been observed in older ( mean age 70 years) self 
testing patients using online decision support. 22  Although these finding are from selected groups of 
patients and may not be generalisable to a broader population, it is reasonable to suggest that 
provision of a decision support system for dosing within an online register may lead to additional 
patient benefits.  The function of the online registry could be further extended to provide  training and 
educational materials and an advice and support forum for patients undertaking PSM including those 
people traveling abroad who can access the database from anywhere in the world. Furthermore, the 
online registry offers the option to prospectively collect additional outcomes such as health related 
quality of life and patient satisfaction. Addition of these features may further encourage patients to 
firstly, undertake this model of care and secondly, contribute longitudinal PSM data to an online 
registry. 
 
Conclusions  
The results of this study essentially indicate that an online registry for PSM of oral anticoagulation is 
feasible, acceptable and accurate although a larger cohort of participants is required to confirm these 
results. Based upon these findings, an online registry for this developing model of care could provide 
a valuable tool to gather real world clinical effectiveness and safety evidence.  
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Take home messages 
• Clinical efficacy of Patient Self Monitoring (PSM) of warfarin therapy has been demonstrated 
in trials. The effectiveness of PSM outside of trial condition is however difficult to capture. 
• PSM patients are willing and able to contribute their data to an online self report registry.  
• A simple online self-report registry could provide an opportunity to gather real world 
effectiveness and safety data related to PSM of warfarin therapy. 
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Table 1. Participant characteristics  
Age at consent, years  (n=45) n (%) 
18-39 
40-59 
60-79 
80 plus 
3 (7) 
13 (29) 
28 (62) 
1 (2) 
Gender (n=45) 
Male 
Female 
31 (69) 
14 (31) 
Condition requiring warfarin (n=44)  
Mechanical Heart Valve  
Atrial Fibrillation  
Deep Vein Thrombosis (DVT)  
Pulmonary Embolism (PE) 
Antiphospholipid syndrome (APS) 
DVT / PE / APS 
21 (48)  
11 (25) 
4 (9) 
5 (11) 
2 (5) 
1 (2) 
Regularly receiving the following medication  (n=44) 
Aspirin 
Amiodarone  
NSAIDS  
No 
4 (9) 
1 (2) 
2 (5) 
37 (84) 
Duration of warfarin, years (n=44) 
<1  
1 – 2  
2 – 3  
3 – 4 
4 – 5 
>5 
1 (2) 
4 (9) 
6 (14) 
8 (18) 
1  (2) 
24 (55) 
Model of care  
Self management* 
Self monitoring # 
 With dosage adjustment advice provided by a  
      Hospital based oral anticoagulation clinic 
      Primary care based oral anticoagulation clinic 
25 (57)  
19 (43) 
 
13 (68)  
6 (32) 
Duration of self management,* years (n=25) 
<1  
1 – 2  
2 – 3  
3 – 4 
4 – 5 
>5 
4 (16) 
3 (12) 
3 (12) 
1 (4) 
3 (12) 
11 (44) 
Duration of self monitoring,# years (n=19) 
<1  
1 – 2  
2 – 3  
3 – 4 
3 (16) 
3 (16)  
7 (37) 
6 (31) 
* Self testing and self dosing, # Self testing only 
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45 patients using PSM provided consent to take part via the online consent form  
45 recorded baseline data related to age and gender  1patient provided age and gender only  44 (98%) recorded:- Email contact details  Full baseline demographic data   Indication & duration of warfarin  Model of care utilised  
42/45(93%) recorded:- Full baseline demographic data, Indication & duration of warfarin Model of care utilised  INR data for at least 3 months  
2 patients did not provide INR data   
3 patients discontinued the study after 3 months  39/45 (87%) recorded full data:  Full baseline demographic data, Indication & duration of warfarin Model of care utilised  INR data for 12 months 
Figure 1.Flow diagram showing how many patients used the online register to record each of 
the study data points 
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